
Alexion Pharmaceuticals, Inc. EBITDA 2011-2026 | ALXN
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Alexion Pharmaceuticals, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 3.11 B | 2.45 B | 1.91 B | 1.12 B | 1.12 B | 799 M | 963 M | 567 M | 454 M | 245 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.11 B | 245 M | 1.27 B |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Assembly Biosciences
ASMB
|
-12 M | $ 28.46 | 3.45 % | $ 319 M | ||
|
Ascendis Pharma A/S
ASND
|
-452 M | $ 221.88 | -0.87 % | $ 5 B | ||
|
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M | ||
|
Axsome Therapeutics
AXSM
|
-166 M | $ 156.92 | -1.23 % | $ 7.81 B | ||
|
Galera Therapeutics
GRTX
|
-20.1 M | - | -32.59 % | $ 7.61 M | ||
|
Pharming Group N.V.
PHAR
|
74 M | $ 15.36 | -0.71 % | $ 7.59 B | ||
|
Autolus Therapeutics plc
AUTL
|
-234 M | $ 1.37 | -4.2 % | $ 350 M | ||
|
Kamada Ltd.
KMDA
|
-696 K | $ 8.5 | -1.39 % | $ 260 M | ||
|
I-Mab
IMAB
|
13.8 M | - | - | $ 866 M | ||
|
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B | ||
|
Benitec Biopharma
BNTC
|
-9.77 M | $ 10.98 | -4.52 % | $ 452 M | ||
|
Inventiva S.A.
IVA
|
-52.1 M | $ 5.78 | -4.3 % | $ 138 M | ||
|
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | ||
|
Compugen Ltd.
CGEN
|
-34.6 M | $ 2.09 | -0.95 % | $ 195 M | ||
|
Tiziana Life Sciences PLC
TLSA
|
-27.4 M | $ 1.21 | -3.97 % | $ 71.5 M | ||
|
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | ||
|
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.18 M | - | -1.52 % | $ 24.7 M | ||
|
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-16.2 M | - | - | $ 26.5 M | ||
|
PainReform Ltd.
PRFX
|
-7.2 M | $ 2.28 | -0.44 % | $ 1.03 M | ||
|
Acorda Therapeutics
ACOR
|
-233 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | ||
|
Foghorn Therapeutics
FHTX
|
-83.1 M | $ 5.0 | 2.25 % | $ 315 M | ||
|
Институт стволовых клеток человека
ISKJ
|
220 M | - | - | - | ||
|
Adverum Biotechnologies
ADVM
|
-136 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
-24.5 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
-35.9 M | - | -9.65 % | $ 45.9 M | ||
|
AbCellera Biologics
ABCL
|
-199 M | $ 3.4 | -3.68 % | $ 1.02 B | ||
|
BioMarin Pharmaceutical
BMRN
|
489 M | $ 54.13 | -1.64 % | $ 10.4 B | ||
|
Curis
CRIS
|
-44.3 M | $ 0.77 | 1.89 % | $ 4.86 M | ||
|
Bellerophon Therapeutics
BLPH
|
-22.4 M | - | -74.18 % | $ 955 K | ||
|
AgeX Therapeutics
AGE
|
-9.76 M | - | -10.17 % | $ 12.2 K | ||
|
Coherus BioSciences
CHRS
|
-180 M | $ 1.52 | -5.59 % | $ 178 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-242 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | ||
|
Burford Capital Limited
BUR
|
242 M | $ 7.7 | -5.87 % | $ 1.29 B | ||
|
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | ||
|
Cellectis S.A.
CLLS
|
-131 M | $ 3.34 | -4.02 % | $ 116 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
-76.7 M | $ 4.24 | -2.97 % | $ 704 M | ||
|
Akouos
AKUS
|
-84.3 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | ||
|
AIkido Pharma
AIKI
|
-11.4 M | - | 1.93 % | $ 17.4 M | ||
|
Cardiff Oncology
CRDF
|
-48.6 M | $ 1.8 | -1.1 % | $ 120 M | ||
|
Allakos
ALLK
|
-190 M | - | - | $ 28.6 M | ||
|
Cabaletta Bio
CABA
|
-73.2 M | $ 2.94 | -3.29 % | $ 3.43 M | ||
|
Iterum Therapeutics
ITRM
|
-18.7 M | $ 0.16 | -5.45 % | $ 3.15 M | ||
|
Brickell Biotech
BBI
|
-6.32 M | - | -5.38 % | $ 6.06 M | ||
|
Allena Pharmaceuticals
ALNA
|
-47.3 M | - | 3.16 % | $ 1.9 M |